GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Beyond the Plaque Trap: How Spinal Cord Drugs, Immune Sleep Fixes, and Smart Injections Are Transforming Global Alzheimer’s Care in 2026
Discover the first-week November 2026 Alzheimer's research breakthroughs. Learn how repurposed spinal cord drugs repair DNA, immune cells restore sleep, 5-year CTAD trial data proves longevity, and smart home healthtech supports caregivers.
Unlocking the Brain: Why NeuroDiscovery Matters and Where to Learn More
Neurodiscovery, in its broadest sense, encompasses the multidisciplinary field dedicated to unraveling the mysteries of the nervous system. It’s a vibrant tapestry woven from threads of neuroscience, biology, chemistry, physics, psychology, computer science, and even engineering. This collaborative effort aims to decipher how the brain develops, functions, and changes throughout life,
The Expanding Horizon: Democratization and Evolving Landscapes in Medical Clinical Trials
This essay explores the latest developments in this ongoing transformation, highlighting the key drivers, emerging trends, and potential challenges in creating a more equitable and efficient clinical trial ecosystem.
Brain2Qwerty's Magnetoencephalography (MEG) System: A Paradigm Shift in Neuroscience Research
Neuroscience research has long sought to unravel the intricate workings of the human brain, aiming to understand the neural basis of cognition, behavior, and consciousness. Among the various neuroimaging techniques available, magnetoencephalography (MEG) stands out for its exceptional temporal resolution, offering a millisecond-by-millisecond glimpse into brain activity.
The Unseen Risk: Navigating the Perilous Path of Clinical Trials
The relentless march of medical advancement is a beacon of hope for millions, a testament to humanity's unyielding desire to conquer disease and extend life. At the forefront of this crusade stands the clinical trial, the crucible in which experimental treatments are rigorously tested. While these trials are often hailed as pivotal steps toward groundbreaking therapies, it is imperative to acknowledge the stark and sometimes devastating reality: participation in clinical trials can carry life-threatening consequences. Beyond the statistics and scientific jargon
Early and Accurate Detection of Neurological Diseases: A Pursuit of Breakthrough Solutions
Early and accurate detection of neurological diseases remains one of the most pressing challenges in modern medicine. Neurodegenerative disorders like Alzheimer’s disease (AD), Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) often present with subtle symptoms in their initial stages, making early diagnosis difficult and delaying timely interventions. As our global population ages, the prevalence of these debilitating conditions is projected to rise dramatically, further emphasizing the urgent need for reliable diagnostic tools.
Triumphant Return: Judge Orders FDA to Restore Vital Clinical Trial Diversity Webpages, Empowering Health Equity!
It is a truly hopeful and significant development in the realm of healthcare and government transparency that a US District Judge has recently ordered the full reinstatement of crucial healthcare resources, including vital webpages dedicated to clinical trial diversity, by the US Food and Drug Administration (FDA) and the Department of Health and Human Services
The $17 Billion Race: Why New Treatments for Alzheimer’s Disease Are Changing the Game
The fight against Alzheimer’s disease (AD) is entering a new, highly competitive phase, driven by recent scientific breakthroughs and a growing global market. While therapies targeting amyloid proteins have recently been validated, there remains a critical and ongoing unmet need for drugs that utilize alternative mechanisms of action. Experts are encouraged to see a broader range of therapeutic options emerging in the pipeline for patients.
The Blood Test "Smoke Detector": How AI Helps Family Doctors Spot Alzheimer’s Early
For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps. This delay is particularly challenging in primary care, where family doctors
Why We Can't Sleep in Early Alzheimer's: The New Science of Brain Inflammation
For years, we have known that people with early-stage Alzheimer’s often struggle to get a good night's rest. For a long time, scientists thought this was simply because of "plaques"—sticky protein buildups called amyloid—clogging up the brain.
Bridging the Gap: How Glassbury AI is Making Medical Research Work for Everyone
At Glassbury AI, we believe health justice starts with inclusion. We are using modern technology to fix this recruitment crisis by building trust and making the process easy to understand for every family.
Alzheimer’s & the GRK2 Enzyme: A Sleeping Key to Brain Energy
Discover how ETH Zurich researchers uncovered GRK2 enzyme aggregates as a novel Alzheimer's target, offering new hope for energy-restoring therapies.
AI Brain Map Predicts Early-Onset Alzheimer's Progression
When most people picture Alzheimer's disease, they imagine an individual in their late 70s or 80s gradually experiencing memory loss. However, Early-Onset Alzheimer's Disease (EOAD) paints a starkly different, often heartbreaking picture. Striking individuals under the age of 65—frequently in their 40s or 50s—EOAD attacks people who are at the very peak of their personal and professional lives.
Unlocking Clinical Equity: How Glassbury AI Meets FDA Diversity Action Plan Mandates in Alzheimer’s Research
Explore how Glassbury AI uses Google Cloud, MedGemma, and Vertex AI Explainable AI to guarantee FDA Diversity Action Plan compliance and accelerate Alzheimer's clinical trial matching.
A Legacy of Mistrust: Understanding and Addressing Vaccine Hesitancy Among People of Color
The recent COVID-19 pandemic has laid bare a stark reality: people of color (POC) are disproportionately hesitant to engage with medical and governmental institutions, particularly regarding vaccinations. This hesitancy, often labeled as "vaccine hesitancy," is not simply a matter of ignorance or fear. It is rooted in a deeply ingrained distrust that stems from a long history of systemic racism and medical discrimination.
The Hurdles in the Path to Cures: The Unique Challenges of Rare Disease Research
Rare diseases, despite affecting millions of people worldwide, often exist in a shadow cast by more prevalent illnesses. Their rarity presents a unique set of challenges for researchers striving to develop effective treatments and cures. From limited funding to small patient populations, the path to conquering rare diseases is fraught with obstacles.
The Role of Government in Fostering a Thriving Entrepreneurial Environment for Drug Research and Development
The United States government plays a pivotal role in shaping the landscape for drug research and development (R&D), fostering an environment where entrepreneurial endeavors can flourish. This blog post delves into the multifaceted ways in which the government contributes to this ecosystem, drawing insights from authoritative sources and expert opinions.
Caregivers and Mental Health: The Unsung Heroes Need Support Too
Caregiving is an act of profound love and dedication, but it can also be a challenging journey filled with emotional, physical, and mental strain.
Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research
Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.
Alzheimer’s Breakthrough: Why Tau-Targeting Therapies Are Changing the Game
Explore how tau-targeting drug Diranersen and a newly diversified research pipeline are reshaping Alzheimer's treatment and slowing cognitive decline.